Výsledky vyhledávání - "Nadezhda V. Kovalenko"

PROGNOSTIC SIGNIFICANCE OF COMORBIDITY IN ASSESSING THE DURATION OF INPATIENT TREATMENT IN PATIENTS WITH PERFORATED ULCER

Autor: Vladimir A. Suvorov, Stanislav I. Panin, Nadezhda V. Kovalenko, Mikhail P. Postolov, Evgeny S. Mikhin, Irina A. Peshkurova

Publikováno v: Journal of Volgograd State Medical University. 19:77-84

Resume. Aim of the study. To assess the effect of perioperative factors on the duration of postoperative inpatient treatment of patients with perforated ulcers in conditions of different comorbidity. Material and methods. A study of the results of su

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::15d23c28c1fc524cf7022439399585d2
https://doi.org/10.19163/1994-9480-2022-19-2-77-84

Zobrazit plný text záznamu

A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer

Autor: Martin Reck, Serhii Shevnia, D. Trukhin, Donghoon Shin, Alexander Luft, Kakha Vacharadze, Nadezhda V. Kovalenko, Fülöp Andrea, Jihye Choi, Anatoliy Hontsa, Igor Bondarenko

Publikováno v: Lung Cancer. 146:12-18

Objectives Efficacy, safety, pharmacokinetics (PK), and immunogenicity of the biosimilar candidate SB8 was compared to its reference product bevacizumab (BEV) in patients with metastatic or recurrent nonsquamous non―small cell lung cancer. Methods

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf410b2cdd654736dabf30ce8d97131f
https://doi.org/10.1016/j.lungcan.2020.05.027

Zobrazit plný text záznamu

A phase III study comparing SB8, a proposed bevacizumab biosimilar, and reference bevacizumab in patients with metastatic or recurrent non-squamous NSCLC

Autor: Martin Reck, A. Hontsa, F. Andrea, Serhii Shevnia, K. Vacharadze, D. Trukhin, Jihye Choi, Alexander Luft, Nadezhda V. Kovalenko, Dong Wook Shin, Igor Bondarenko

Publikováno v: Annals of Oncology. 30:v644-v645

Background SB8 is a proposed biosimilar of the reference bevacizumab (BEV). This study compared the efficacy, safety, pharmacokinetics (PK), and immunogenicity of SB8 to BEV in patients with metastatic or recurrent non-squamous non-small cell lung ca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cc9c8c24a32c1cfc8d8fb860360e9662
https://doi.org/10.1093/annonc/mdz260.087

Zobrazit plný text záznamu

Plinabulin (Plin), a small molecule with anti-cancer activity and a novel mechanism of action (MoA) in docetaxel (Tax)-induced neutropenia: Phase (φ) 2 results from a head-to-head comparison with Pegfilgrastim (Peg)

Autor: Ramon Mohanlal, Igor Bondarenko, Yuankai Shi, Qingyuan Zhang, Douglas W. Blayney, Lihua Du, Mikhail V. Kopp, Nadezhda V. Kovalenko, Jifeng Feng, Lan Huang, Ihor Vynnychenko, Stephan Ogenstad

Publikováno v: Journal of Clinical Oncology. 36:2528-2528

2528Background: Plin has clinical anticancer activity in combination with Tax (Mohanlal ASCO-SITC 2017,18). Plin prevented Tax-induced neutropenia in a post-hoc analysis of a φ 2 trial (Blayney ASH...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::42ec4e2eb7a2cef1eaceaaf7804f2d1d
https://doi.org/10.1200/jco.2018.36.15_suppl.2528

Zobrazit plný text záznamu

Pharmacokinetics and safety of BCD-021, bevacizumab biosimilar candidate, compared to Avastin in patients

Autor: Aleksandr P. Pecheniy, Irina A. Jelvakova, Oleg Gladkov, Sergey Orlov, Nadezhda V. Kovalenko, Bogdan Kotiv, Andrey V. Khorinko, Marina Nechaeva, Tatiana I. Prokopenko, Ludmila P. Sheveleva, Julia S. Shapovalova, Olga Filon, Daniil L. Stroyakovsky, Olga Burdaeva, Sergei Tjulandin, Mikhail V. Kopp, Roman Ivanov

Publikováno v: Journal of Clinical Oncology. 32:e13500-e13500

e13500 Background: BCD-021 is a bevacizumab biosimilar candidate manufactured by CJSC BIOCAD, Russia. Full spectrum of physicochemical and preclinical studies showed equivalence of BCD-021 to innov...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a5d995f14ef6ad2b1865aedb78354525
https://doi.org/10.1200/jco.2014.32.15_suppl.e13500

Zobrazit plný text záznamu

Efficacy and safety of BCD-017, a novel pegylated filgrastim: Results of open-label controlled phase II study in patients with breast cancer receiving myelosuppressive chemotherapy

Autor: Roman Ivanov, Irina Koroleva, Olga V. Salafet, T. V. Chernovskaya, Olga Burdaeva, Andrey V. Khorinko, Elena G. Ovchinnikova, Ludmila P. Sheveleva, Tatiana I. Prokopenko, Marina Nechaeva, Marina Matrosova, Nadezhda V. Kovalenko

Publikováno v: Journal of Clinical Oncology. 31:e20593-e20593

e20593 Background: Pegfilgrastim (conjugate of filgrastim and 20 kDa polyethylene glycol (PEG) is approved for treatment of chemotherapy-associated neutropenia. BCD-017 (empegfilgrastim) is a covalent conjugate of filgrastim with 30 kDa PEG. Increase

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4badb1869bf025ec2d06496a5ec3b177
https://doi.org/10.1200/jco.2013.31.15_suppl.e20593

Zobrazit plný text záznamu

Safety of front-line bevacizumab (BEV) combined with weekly paclitaxel (wPAC) and q3w carboplatin (C) for ovarian cancer (OC): Results from OCTAVIA

Autor: Octavia Investigators, Ana Oaknin, Daniel Stroyakovsky, Bengt Tholander, J. G. M. Segalla, Frédéric Selle, David T. Bollag, Antonio González-Martín, Laurence Gladieff, An K.L. Reyners, Martin Gore, Nadezhda V. Kovalenko, Sandro Pignata

Publikováno v: Journal of Clinical Oncology. 30:5017-5017

5017^ Background: In two randomized phase III trials in OC (GOG218 and ICON7), front-line BEV + q3w PAC + q3w C followed by BEV alone significantly improved progression-free survival (PFS) vs chemotherapy (CT) alone. In the Japanese NOVEL trial, wPAC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e513e465af202fd4a7232399e44f1f66
https://doi.org/10.1200/jco.2012.30.15_suppl.5017

Zobrazit plný text záznamu

LUX-breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab (T) and/or lapatanib (L)

Autor: Martina Uttenreuther-Fischer, Tamas Hickish, Chiun-Sheng Huang, Nadezhda V. Kovalenko, Dmitry P. Udovitsa, K Pelling, Janice Tsang, Ling-Ming Tseng, Ajay O. Mehta

Publikováno v: Journal of Clinical Oncology. 30:TPS651-TPS651

TPS651 Background: Management of HER2-overexpressing MBC has improved over the past decade. However, pts still develop resistance to currently available HER2-targeted therapies and novel effective treatments are increasingly required as dual targeted

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e43145026339476c7fa714b4c7926304
https://doi.org/10.1200/jco.2012.30.15_suppl.tps651

Zobrazit plný text záznamu

Efficacy and safety of empegfilgrastim, a novel pegylated G-CSF: Results of complete analysis after 4 cycles of myelosuppressive chemotherapy in phase III double-dummy randomized clinical study

Autor: Sergey Panchenko, Sergei Tjulandin, Julia S. Shapovalova, Olga Filon, Daniil Stroyakovskiy, Marina Nechaeva, Petr Krivorotko, Olga Burdaeva, Guzel Mukhametsina, Marina Matrosova, Ludmila P. Sheveleva, Igor Lifirenko, Vladimir Ivanovich Vladimirov, Nadezhda V. Kovalenko, Roman Ivanov, Mikhail V. Kopp, Pavel Skopin, Anastasia Abrosimova, Irina A. Jelvakova

Publikováno v: Web of Science

e20735 Background: Empegfilgrastim is an innovator drug product of pegylated G-CSF indicated for prophylaxis of neutropenia in patients receiving myelosuppressive chemotherapy. Methods: Objective w...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7b48118a4cab5cb537488669c9372ed
https://publons.com/wos-op/publon/18351161/

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání